The Week in Review: Mindray Medical Continues on Acquisition Path
Posted on June 09, 2012 at 06:43 AM EDT
Mindray Medical paid $35.5 million for a controlling stake in Wuhan Dragonbio Surgical Implant, an orthopedics implant maker; Chongqing Zhifei Biological Products and Merck expanded their vaccine partnership to include Merck’s rotavirus vaccine; four clinical-stage CROs, one each from China, Japan, South Korean and Taiwan, have banded together to form the Alliance for Pacific Asia Clinical Trials (A-PACT); ShangPharma and Eli Lilly celebrated ten years of drug development partnership; WuXi PharmaTech reported that a former China employee has been convicted for the theft of chemical compounds; India is considering taking steps to reduce its dependence on APIs and intermediates from China; and Hutchison MediPharma released positive Phase I data for its two most advanced anti-cancer drugs. More details…. Stock Symbols: (NYSE: MR) (SHE: 300122) (NYSE: MRK) (NYSE: SHP) (NYSE: LLY) (NYSE: WX) (AIM: CHM) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here